Home / People / Hannah Curtis
Portrait ofHannah Curtis

Hannah Curtis

Partner

CMS Cameron McKenna Nabarro Olswang LLP
2 College Square
Anchor Road
Bristol
BS1 5UE
United Kingdom
Languages English

Hannah Curtis is a partner in the Technology & Media Team and a member of the firm’s Life Sciences Sector Group. Hannah works across a number of sectors but has a particular focus on life sciences & healthcare, having studied biological sciences prior to law.

Hannah has more than fifteen years’ experience of advising on a broad range of transactions and in particular those with an intellectual property focus within the life sciences sector. She specialises in commercial agreements relating to licensing, sales and distribution, research and development, manufacturing and supply, collaborations, alliances and joint ventures. During her time with the firm Hannah has been on secondment to the Wellcome Trust, Pfizer and the Nestlé Institute of Health Sciences.

more less

Relevant experience

  • hVIVO plc on its significant equity investment into PrEP Biopharm (a development stage biopharmaceutical company) and also on PrEP’s licensing arrangements to enable PrEP to develop and commercialise a prophylactic compound (“PrEP-001”) on a worldwide basis.
  • The Francis Crick Institute in relation to the transfer and licence of research activities, intellectual property and other assets between the joint venture partners to the Crick.
  • Nestlé Health Science on a licence agreement with Lipid Therapeutics for exclusive rights to develop and commercialise LT-02 - a new therapeutic approach that has shown success in treating mild-to-moderate ulcerative colitis.
  • Three of the UK’s leading retail banks on the renegotiation of their joint venture arrangement with Unisys for the provision by Intelligent Processing Solutions (iPSL) of cheque processing services to the banks’ groups and Unisys Payment Services’ customers.
  • Futura Medical, an AIM listed company, in relation to the licensing of the manufacture and distribution of its CSD500 product to major pharmaceutical and healthcare groups.
  • Sinclair IS Pharma plc on an exclusive 100 year licence and distribution arrangement with an affiliate of Valeant Pharmaceuticals International, Inc, for injectable aesthetic dermal filler products in Western Europe.
  • Chugai Pharma Marketing Ltd., a wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd., in relation to the license of exclusive commercialization rights to Swiss-based Helsinn group's innovative ghrelin receptor agonist, anamorelin, for the three major European pharmaceutical markets.
  • Bayer CropScience GmbH in relation to the sale of its Norwich-based manufacturing business (now Briar Chemicals Limited) to the Aurelius group.
  • Takeda Pharmaceutical on its €9.6 billion acquisition of Swiss drug company, Nycomed.
  • Medtronic on the distribution agreement with Tissuemed for Medtronic to be appointed as exclusive distributor of Obex NeuroFilm™ Cerebrospinal Fluid Barrier in markets outside the US.
more less

Memberships & Roles

  • ABPI
  • Biotech Industry Association
  • Tech UK - Data Analytics and AI Leadership Committee
more less

Publications

  • Bioscience Law Review 
more less

Education

  • 2006 - Legal Practice Course, BPP, London
  • 2005 - Graduate Diploma in Law, BPP, London
  • 2004 - BSc Biology with a Year in Europe, Imperial College, London
more less

Feed

08/12/2023
COP28 Update – 8 December 2023
COP28 has seen a host of pledges and agreements, and the CMS team has been reflecting on the announcements and sharing their experiences of COP28 on the CMS COP28 Hub. Here, we roundup the latest commentary...
08/12/2023
COP28: Global Health Under the Spotlight
Health took centre stage at the first ever ‘Health Day’ at COP28 on 3 December. The program focused the attention of world leaders on the profound public health-related issues stemming from climate...
16/11/2023
On the Pulse Webinar Series 2023 - Autumn
On the Pulse webinar series brings you updates on the latest legal and commercial developments in the life sciences & healthcare sector. The Autumn edition will see our CMS sector specialists cover: Commercial - Deal landscape and transaction trends in the Life Sciences SectorDispute Resolution - The midnight clause: why choice of law and jurisdiction clauses matterPublic Procurement - Typical pitfalls to be avoided in a procurement process for pharma and medical devices suppliesequIP - Pitfalls for life sciences start-ups to avoidEach webinar will be one hour in length with a 15-minute Q&A session. To register for the full series or just the topics of interest to you, click on the registration links below. To watch the Spring webinars in the On the Pulse series, visit here.
12/09/2023
UK Re-joins Horizon Europe
On 7 September, the UK re-joined the world’s largest research collaboration programme, Horizon Europe. The decision has been welcomed by academics and life sciences businesses within the UK and the...
13/06/2023
Healthy Horizons Webinar Series
The Life Sciences & Healthcare sector is under increased scrutiny from an ESG-perspective, with pressure faced in every aspect of the value chain. Healthy Horizons, our practical guide to doing responsible...
25/05/2023
ESG contractual clauses – ensuring compliance within your supply chains
Life Sciences & Healthcare companies are responding to pressure from a variety of stakeholders to adopt ESG strategies by reviewing all aspects of their business - from procurement to product development...
11/05/2023
ESG contractual clauses – ensuring compliance within your supply chains
Life Sciences & Healthcare companies are responding to pressure from a variety of stakeholders to adopt ESG strategies by reviewing all aspects of their business - from procurement to product development, supply chain to service delivery.  Examining existing and future relationships with suppliers is a key part of ESG-compliance.  A common method adopted by Life Sciences & Healthcare companies is the inclusion of ‘ESG clauses’.  These clauses can legally require the supplier to align with ESG requirements, in­clud­ing: re­port­ing on environmental mat­ters; re­du­cing greenhouse gas emis­sions;set­ting targets for a transition to net zero emissions; andmaintaining a minimum ESG sustainability rating for the life of the contract. This article explores the various types of ESG clauses, how they can be enforced and the next steps for businesses operating in the Life Sciences & Healthcare sector.
09/03/2023
Government outlines its strategy to improve access to patient healthcare...
The Department of Health and Social Care (“DHSC”) published its medical technology strategy in February 2023. This is the first strategy published which recognises the importance of leveraging the...
11/01/2023
Healthy Horizons
The Life Sciences & Healthcare sector is under increased scrutiny from an ESG-perspective, with pressure faced by every aspect of the value chain.  The attention on each of the three pillars of ESG provides an opportunity for businesses to demonstrate ESG excellence, create business value through fair and responsible working practices, and be a lever for growth as well as societal good. Our practical guide on responsible business within the Life Sciences & Healthcare sector is accessible on this page.  Our Healthy Horizons content will be made available as it is published, exploring topics ranging from governance, sustainable finance & responsible investment in the sector to responsible approaches to marketing, risk & reputation.  If there is a topic you’d like to discuss further, please do get in touch.  We advise our Life Sciences & Healthcare clients – from multinationals to start ups – in all areas of ESG-related law and would be delighted to speak.
05/07/2022
Government publishes a plan for Digital Health and Social Care
Introduction The Government have published a Plan for Digital Health and Social Care (the “Plan”) in England that aims to ensure that the NHS is ‘set up to meet the challenges of 2048, not of 1948’...
10/02/2021
Life Sciences - The road to recovery
Covid-19 has put the life sciences industry in the spotlight. The sector has pulled together to care for those impacted by the virus and in the race to find a vaccine. There have been col­lab­or­a­tions...
07/01/2021
Greening your supply chain
Many businesses want to turn the impact of COVID-19 on their supply chains into an opportunity to improve efficiency and increase margins. They can do so by integrating sustainable environmental processes...